drugset
drugset / Trial / NCT04846920

A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)

NCT04846920 ↗

Phase 1 Completed 29 enrolled Merck Sharp & Dohme LLC
Non-randomizedSequentialOpen-labelTreatment

Summary

The goal of this study is to evaluate the safety, tolerability and pharmacokinetics of escalating doses of belzutifan as second line positive (2L+) treatment in participants with advanced clear cell renal cell carcinoma (ccRCC).

Timeline

Start
2021-06-14
Primary completion
2026-04-11
Completion
2026-04-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Belzutifan Small molecule 120 mg Oral
Subject Belzutifan Small molecule 160 mg Oral
Subject Belzutifan Small molecule 200 mg Oral

Indications

clear cell renal carcinoma